Abstract
The integrins comprise a multifaceted family of membrane-associated proteins that regulate cellular adhesion, motility and cytokinesis. Higher levels of integrin beta-6 predict poorer outcomes in patients with solid tumors such as colorectal, non-small cell lung, gastric and cervical cancers. The vedotin SGN-B6A is an investigational antibody–drug conjugate designed to deliver the cytotoxic agent monomethyl auristatin E (MMAE) to integrin beta-6-expressing cells. Once internalized, intracellular MMAE disrupts microtubules causing cell cycle arrest and apoptosis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have